Bagsvaerd - On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the 'Safe Harbour Rules').

This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.

Under the programme, initiated 5 November 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 November 2019 to 3 February 2020.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 15 November 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 38,618,923 B shares at an average share price of DKK 341.82 per B share equal to a transaction value of DKK 13,200,811,795.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Contact:

Anne Margrethe Hauge

Tel: +45 4442 3450

Email: amhg@novonordisk.com

(C) 2019 Electronic News Publishing, source ENP Newswire